Tactile Systems Technology
TCMD on Nasdaq. Tactile Systems Technology sells at-home medical devices for chronic diseases to patients. Market value $509m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Worth a closer look
Why it could be worth it
What to watch out for
Nothing stood out in the numbers we check.
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $5.34 of spare cash in the past 12 months. A savings account pays about $4.
You pay 12.4 years of operating profit for the business. The average large US company costs around 18.
The filings do not give us enough to work this out.
Quality score: 78 of 100. Price score: 89 of 100. Our list needs 70 on quality and 60 on price.
$22.19 a share, 59% above its 1-year low
Over the past year the price has ranged from $14.00 to $37.77.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: $27 million in the past 12 months, $40 million in the year to December 2025.
| Revenue | |||||
| Revenue | $208m | $247m | $274m | $293m | $330m |
| Operating margin | |||||
| Operating margin | -0.8% | -5.2% | 6.6% | 7.6% | 8.9% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | 0.09 | n/a | 0.00 |
| Shares outstanding | |||||
| Shares outstanding | 0.02bn | 0.02bn | 0.02bn | 0.02bn | 0.02bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)7 of 8 checks we could run
- Profit backed by cash (accruals)Yes
- Debt0.00× equity
- Revenue growth, five yearsStrong, 12.0% a year
- Buying back its own sharesNo, 12% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $86 million last quarter, up 9% on a year ago.
- Profit: $8 million, up 142% on a year ago.
- It keeps 10 cents of each $1 of sales as operating profit, up from 6 cents a year earlier.
- Spare cash over the past 12 months: $27 million, down from $40 million.
- 1% fewer shares than a year ago. Each share owns a bit more of the company.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $73m |
| December 2024 | $86m |
| March 2025 | $61m |
| June 2025 | $79m |
| September 2025 | $86m |
| December 2025 | $104m |
| March 2026 | $75m |
| June 2026 | $86m |
| Quarter to | Amount |
|---|---|
| September 2024 | $5m |
| December 2024 | $10m |
| March 2025 | -$3m |
| June 2025 | $3m |
| September 2025 | $8m |
| December 2025 | $11m |
| March 2026 | -$2m |
| June 2026 | $8m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 17 February 2026
- Next quarterly (estimated, 10-Q)
- 9 November 2026
Who owns it
2 long-term investors we follow own it, up from 1 last quarter. 181 funds in all.
- LSV Asset ManagementJosef Lakonishok
- Value
- $14m
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| LSV Asset ManagementJosef Lakonishok | $14m | <0.1% | |
| Royce & AssociatesChuck Royce | $2m | <0.1% | New |
Largest holders overall
- BlackRock$57mAdded
- Cadian Capital Management, LP$47mAdded
- Dimensional Fund Advisors LP$33m
- Morgan Stanley$29mCut
- Vanguard Capital Management$29mAdded
- Driehaus Capital Management$28mAdded
- Acadian Asset Management$27m
- Vanguard Portfolio Management$21mAdded
- Federated Hermes$20mAdded
- Arrowstreet Capital, Limited Partnership$19m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- BlackRock, Inc.Passive investor7.7%Since 31 March 2025
- Cadian Capital Management, LPPassive investorat least 7.0%+2.1 pts(filed with 2 related holders)Since 30 June 2026
- Morgan StanleyPassive investorat least 3.7%−2.1 pts(filed with 1 related holder)Since 30 June 2026
- Dimensional Fund Advisors LPPassive investorSold down below 5%Since 31 December 2025
- PARADIGM CAPITAL MANAGEMENT INC/NYPassive investorSold down below 5%Since 31 December 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
BlackRock, Inc. Passive investor | 7.7% | 31 March 2025 | |
Cadian Capital Management, LP Passive investor | at least 7.0%+2.1 pts (filed with 2 related holders) | 30 June 2026 | |
Morgan Stanley Passive investor | at least 3.7%−2.1 pts (filed with 1 related holder) | 30 June 2026 | |
Dimensional Fund Advisors LP Passive investor | Sold down below 5% | 31 December 2025 | |
PARADIGM CAPITAL MANAGEMENT INC/NY Passive investor | Sold down below 5% | 31 December 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 3 sold $2m, $148,260 of it under preset trading plans.
- Dodd Sheri LouiseChief Executive Officer, DirectorSold
- Date
- 10 August 2026
- Shares
- 10,978
- Price
- $29.44
- Value
- $323,243
- Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERSold
- Date
- 11 May 2026
- Shares
- 4,631
- Price
- $24.49
- Value
- $113,413
- Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERSold
- Date
- 24 February 2026
- Shares
- 7,701
- Price
- $28.94
- Value
- $222,867
- Burns KristieSr. VP Mktg & Clinical AffairsSold
- Date
- 24 February 2026
- Shares
- 6,246
- Price
- $28.94
- Value
- $180,759
- Dodd Sheri LouiseChief Executive Officer, DirectorSold
- Date
- 24 February 2026
- Shares
- 10,993
- Price
- $28.94
- Value
- $318,137
- Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERSold
- Date
- 23 February 2026
- Shares
- 5,518
- Price
- $28.29
- Value
- $156,129
- Burns KristieSr. VP Mktg & Clinical AffairsSold
- Date
- 23 February 2026
- Shares
- 4,439
- Price
- $28.29
- Value
- $125,601
- Dodd Sheri LouiseChief Executive Officer, DirectorSold
- Date
- 23 February 2026
- Shares
- 15,240
- Price
- $28.29
- Value
- $431,207
- Burns KristieSr. VP Mktg & Clinical AffairsSoldunder a preset trading plan
- Date
- 2 January 2026
- Shares
- 5,139
- Price
- $28.85
- Value
- $148,260
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 10 August 2026 | Dodd Sheri Louise Chief Executive Officer, Director | Sold | 10,978 | $29.44 | $323,243 |
| 11 May 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sold | 4,631 | $24.49 | $113,413 |
| 24 February 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sold | 7,701 | $28.94 | $222,867 |
| 24 February 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sold | 6,246 | $28.94 | $180,759 |
| 24 February 2026 | Dodd Sheri Louise Chief Executive Officer, Director | Sold | 10,993 | $28.94 | $318,137 |
| 23 February 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sold | 5,518 | $28.29 | $156,129 |
| 23 February 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sold | 4,439 | $28.29 | $125,601 |
| 23 February 2026 | Dodd Sheri Louise Chief Executive Officer, Director | Sold | 15,240 | $28.29 | $431,207 |
| 2 January 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sold under a preset trading plan | 5,139 | $28.85 | $148,260 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 17 Feb 2026, plus the 10-Q filed 10 Aug 2026 and 5 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
What changed in the risks this year
Companies must list what could hurt them each year. These are the parts that changed since last year’s report.
Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .
Could happenWe are also exposed to the risk that generative AI may produce incorrect outputs, release confidential information, reflect biases, infringe intellectual property, or otherwise cause harm. Their complexity makes it challenging to understand outputs and comply with documentation or explanation requirements. Any of these risks could expose us to liability or adverse legal or regulatory consequences and harm our business or financial results.
Read moreFailure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .
Could happenThe use of AI developed by third parties introduces risks related to how the AI is developed, trained, and deployed, including unauthorized material in training data and limited visibility into risk mitigation steps.
Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .
Could happenThe medical device industry is highly competitive and subject to rapid change and technological advancements. Therefore, it is important to our business that we continue to evaluate technology to determine whether it may help us compete on a cost-effective basis. The cost of investing in, implementing and maintaining such technology is high, and there can be no assurance, given the fast pace of change and innovation, that our technology, either purchased or developed internally, will meet our needs, in a timely and cost-effective manner or at all. During the course of implementing new technology into our operations, we may experience system interruptions and failures. In addition, there can be no assurance that we will recognize, in a timely manner or at all, the benefits that we may expect as a result of our implementing new technology. If we are not able to anticipate and keep pace with existing and future technology needs, our business, financial results, or reputation could be negatively impacted.
Read moreChanges in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, authorized or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could adversely impact our business.
The ability of the FDA to review and provide marketing authorization new products or changes to existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, federal government shutdowns, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund R&D activities is subject to the political process, which is inherently fluid and unpredictable. Decreases in government funding of research and development, including any reductions in funding to the U.S. National Institutes of Health may impact our business, as could changes in government programs that provide funding to research institutions and companies, including changes in the amount of funds allocated to different areas of research or changes that have the effect of increasing the length of time of the funding process. Disruptions at the FDA and other agencies may also slow the time necessary for new products, or modifications to authorized products, to be reviewed and/or authorized by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could adversely affect our business .
Read moreFailure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results .
Could happenOur industry continually experiences technological changes, with frequent introductions of new technology-driven products and services, including recent and rapid developments in artificial intelligence ("AI"). There are risks in effectively implementing and marketing new technology-driven products and services. Upgrades and integration may cause service interruptions, transaction errors, and delays, and could cause us to fail to comply with applicable laws. There can be no assurance that we will be able to successfully manage the risks associated with an increased dependency on technology. Failure to successfully keep pace with technological change affecting our industry could negatively affect our revenue and profitability.
Read more
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.